RxDoctor Payments DataLook up a doctor →

Gregory Marcotte, MD

Allergy & Immunology · Wilmington, DENPI 1861470767

Payments from drug & device makers

$16,723in general payments, 2019–2025

Across 790 payments — averaging $21.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$3K
  • GSK$2K
  • Regeneron Healthcare Solutions, Inc.$1K
  • Biocryst US Sales Co., LLC$1K
  • Pfizer$1K
  • CSL Behring$1K
  • plus $7K from 39 others

What the payments were for

  • Consulting fees$750%
  • Food & beverage$16,14497%
  • Education$5033%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few allergy & immunology providers in Delawareto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$557,904
Medicare patients
1,060
Services billed
24,457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab45$153,302
Trelegy ElliptaFluticasone/Umeclidin/Vilanter142$132,285
Breztri AerosphereBudesonide/Glycopyr/Formoterol65$59,413
Dupixent SyringeDupilumab15$56,090
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5012$56,058
Advair HfaFluticasone Propion/Salmeterol84$45,183
Arnuity ElliptaFluticasone Furoate74$35,270
Breo ElliptaFluticasone/Vilanterol48$28,441
Azelastine Hcl376$18,213
Pulmicort FlexhalerBudesonide37$15,449
Fluticasone Propionate HfaFluticasone Propionate22$12,019
Wixela InhubFluticasone Propion/Salmeterol52$9,987
Spiriva RespimatTiotropium Bromide16$9,010
SymbicortBudesonide/Formoterol Fumarate22$8,857
Montelukast Sodium539$8,614

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Arnuity Ellipta, Breo Ellipta, Incruse Ellipta$2,191$202,191276 claims
AstraZenecaBreztri Aerosphere, Pulmicort Flexhaler, Symbicort$2,867$83,719124 claims
CSL BehringPrivigen$1,038$56,05812 claims
Boehringer IngelheimSpiriva Respimat$71$9,01016 claims
Hikma Pharmaceuticals USAEpinephrine$13$6,72040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few allergy & immunology providers in Delawareon file to place this against a meaningful peer group, so we don't.

Other allergy & immunology in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →